Medytox said that the Ministry of Food and Drug Safety has approved to sell Innotox 100 unit, the company's liquid-type botulinum toxin (BTX) A-Type product, in the domestic market.
With the approval, Medytox has secured a lineup of various capacities, along with the existing 25 and 50 units, and increased the capacity utilization rate of its second plant, which exclusively manufactures BTX products under U.S. current good manufacturing practice guidelines.
Innotox is the world's first liquid botulinum toxin type A drug developed by Medytox in 2014. It is a botulinum toxin product that enhances safety by eliminating human serum albumin and animal-derived substances in the manufacturing process.
The BTX comes out in a liquid-type formulation and can be used immediately without a separate dilution process, further improving the convenience of treatment and having the advantage of more accurate treatment capacity calculation, Medytox said.
"The sales approval for Innotox 100 unit is significant as it has allowed the company to secure a lineup of various capacities, and help the company meet consumer needs better," Medytox CEO Jung Hyun-ho said. "Clinical trials are underway to secure additional indications for Innotox and accelerate the company's advance to the premium BTX market."
The company also plans to unveil a new prefilled syringe-type BTX, Jung said.